Market Access News | pharmaphorum

News

Genetic engineeering concept with 3d rendering robotic hand editing dna helix

PTC gets green light for gene therapy Upstaza in EU

PTC Therapeutic's Upstaza gene therapy for patients with genetic disorder AADC deficiency has been recommended for approval in the EU, setting up another test of the commercial prospects f

News

CHMP backs Sanofi's Xenpozyme as first drug for ASMD

Sanofi's Genzyme unit has moved a step closer to securing EU approval for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after scoring

News

AbbVie files continuous Parkinson's therapy ABBV-951 in US

AbbVie has filed for approval of its therapy for Parkinson's disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to

News

Dupixent claims new territory in eosinophilic oesophagitis

Sanofi and Regeneron have added another string to the bow of their immunology blockbuster Dupixent with an FDA approval in eosinophilic oesophagitis (EoE), which could help the drug reach i

News

Sleepio app for insomnia backed by NICE

After a non-committal appraisal of Big Health's Sleepio app for insomnia last November in draft guidance from NICE, the cost-effectiveness agency has come out in favour of the digital thera

News

Coalition aims to improve cancer drug access in poorer natio...

Several of the top pharmaceutical companies have joined a new coalition that aims to improve access to cancer medicines in low- and lower-middle-income countries (LLMICs).

PTC gets green light for gene therapy Upstaza in EU

CHMP backs Sanofi's Xenpozyme as first drug for ASMD

AbbVie files continuous Parkinson's therapy ABBV-951 in US

Dupixent claims new territory in eosinophilic oesophagitis

Sleepio app for insomnia backed by NICE

Coalition aims to improve cancer drug access in poorer natio...

FDA starts review of Regeneron's drug for rare disease FOP

How to meet your physicians where they are online

News

Editor's Picks